Discontinued — last reported Q4 '23
Edwards Lifesciences Rest of World — Long-lived tangible assets increased by 6.6% to $353.50M in Q4 2023 compared to the prior quarter. Year-over-year, this metric grew by 6.6%, from $331.60M to $353.50M.
An increase suggests capital expansion or infrastructure investment in the region, while a decrease may indicate asset divestiture, depreciation, or a shift toward asset-light distribution models.
This metric represents the book value of non-current, physical assets held by the company within a specific geographic o...
Peers in the medical device industry typically report similar figures under 'Property, Plant, and Equipment' categorized by geographic region, allowing for comparison of regional manufacturing and operational intensity.
ew_segment_rest_of_world_long_lived_tangible_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q4 '22 | Q4 '23 | |
|---|---|---|---|---|---|
| Value | $316.60M | $330.90M | $335.50M | $331.60M | $353.50M |
| QoQ Change | — | +4.5% | +1.4% | -1.2% | +6.6% |
| YoY Change | — | — | — | -1.2% | +6.6% |